Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13609474 | 0.91 | DRD2 (0.60) | DRD2SIGMAR1CACNA1HTDP1MEN1 | |
| SCHEMBL8254760 | 0.87 | DRD2 (0.64) | DRD2SIGMAR1CACNA1HTDP1MEN1 | |
| SCHEMBL18851206 | 0.86 | DRD2 (0.56) | DRD2SIGMAR1CACNA1HTDP1MEN1 | |
| SCHEMBL29263630 | 0.86 | DRD2 (0.62) | DRD2SIGMAR1MAOAMAOBTDP1 | |
| SCHEMBL13075277 | 0.85 | DRD2 (0.56) | DRD2SIGMAR1MAOAMAOBCACNA1H | |
| SCHEMBL13202614 | 0.85 | DRD2 (0.59) | DRD2SIGMAR1CACNA1HTDP1MEN1 | |
| SCHEMBL5429289 | 0.84 | DRD2 (0.57) | DRD2SIGMAR1MAOAMAOBCACNA1H | |
| SCHEMBL31376118 | 0.83 | DRD2 (0.56) | DRD2SIGMAR1MAOAMAOBCACNA1H | |
| SCHEMBL9127008 | 0.82 | DRD2 (0.60) | DRD2SIGMAR1CACNA1HTDP1MEN1 | |
| SCHEMBL16708685 | 0.81 | DRD2 (0.59) | DRD2SIGMAR1CACNA1HTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | DRD2 1063/4885SIGMAR1 3068/4885MAOA 4421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.